Impres Medical Inc. has raised $3 million from the sale of convertible debt and stock options, according to documents recently filed with the Securities and Exchange Commission. The startup, based in Minnetonka, Minn., is developing an implantable device to stop severe cramping (dysmenorrhea) and heavy bleeding (menorrhagia) in women by “deactivating” the endometrium, the inner […]
Impres' device goes into the bottom of the uterus and deactivates the patient’s menstrual period. It's specifically focused on women who won't have any more children and works as an alternative to hysterectomy or endometrial ablation, a process that which destroys the lining of the womb.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.